News
CDNA
7.56
-5.26%
-0.42
Weekly Report: what happened at CDNA last week (0415-0419)?
Weekly Report · 3d ago
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CareDx granted an option to purchase 700,706 shares of CareDx’s common stock to John Hanna on April 15, 2024. The Transplant Company is a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers.
Barchart · 6d ago
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
NASDAQ · 04/18 07:47
CareDx Price Target Maintained With a $15.00/Share by Stephens & Co.
Dow Jones · 04/17 14:21
Stephens & Co. Reiterates Overweight on CareDx, Maintains $15 Price Target
Benzinga · 04/17 14:11
CareDx Appoints John W. Hanna as New CEO and Board Member
TipRanks · 04/16 20:32
CareDx Name John Hanna as Chief Executive
John Hanna previously served as CEO of Apton Biosystems. CareDx named John Hanna as its new president and chief executive, effective April 15. The company has been looking for a new CEO since November. Hanna replaces Reginald Seeto, who stepped down.
Dow Jones · 04/16 20:19
CareDx appoints John Hanna as president and CEO
Seeking Alpha · 04/16 20:07
*CareDx: Hanna Named to Board of Directors>CDNA
Dow Jones · 04/16 20:03
*CareDx: Hanna Appointments Effective April 15 >CDNA
Dow Jones · 04/16 20:03
CAREDX- APPOINTED JOHN W. HANNA AS ITS NEW PRESIDENT AND CEO, EFFECTIVE APRIL 15, 2024
Reuters · 04/16 20:02
*CareDx Appoints John W. Hanna As Its New President And Chief Executive Officer >CDNA
Dow Jones · 04/16 20:02
*CareDx Appoints John W. Hanna as Its New Pres and CEO > CDNA
Dow Jones · 04/16 20:02
Weekly Report: what happened at CDNA last week (0408-0412)?
Weekly Report · 04/15 11:02
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Illumina CFO Joydeep Goswami to depart, former Summit Therapeutics exec Ankur Dhingra to succeed. Gene sequencing company Illumina says he will be succeeded by former Summit executive. Company has reaffirmed its forecast for the first quarter and full-year 2024.
Reuters · 04/09 21:28
Weekly Report: what happened at CDNA last week (0401-0405)?
Weekly Report · 04/08 11:07
How CareDx (CDNA) Stock Stands Out in a Strong Industry
NASDAQ · 04/01 12:40
Weekly Report: what happened at CDNA last week (0325-0329)?
Weekly Report · 04/01 11:05
Weekly Report: what happened at CDNA last week (0318-0322)?
Weekly Report · 03/25 11:08
Weekly Report: what happened at CDNA last week (0311-0315)?
Weekly Report · 03/18 11:06
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.